NCT03438279已完成不适用
Projecting Survival for Patients Treated With First-Line Ipilimumab-Nivolumab Combination Therapy Using a Prognostic Model and Cost Per Responder Model of Ipilimumab-Nivolumab Combination Therapy
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2015年6月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- Prognostic Model of Overall Survival (OS)
研究概览
简要总结
This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of melanoma
排除标准
- •Age less than 18 years old
结局指标
主要结局
Prognostic Model of Overall Survival (OS)
时间窗: 10 years
The OS prognostic model uses Individual patient data from a pooled analysis of 12 ipilimumab studies.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Overall Survival and Disease-free Survival in Breast Cancer Patients Under COSBreast CancerNCT02745262IVI Vigo400
招募中
不适用
A Prospective, Pre-market, Multi-center Study of Insignia Hip Stem in THA to Determine Implant Survivorship and PROMS.Arthritis (E.G., Degenerative Joint Disease (DJD), Osteoarthritis, and Rheumatoid Arthritis (RA))NCT06108934Stryker Australia Pty Ltd.313
已完成
不适用
Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016Soft Tissue Sarcoma AdultNCT03833037Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau102
已完成
不适用
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT03896984Bayer346
已完成
2 期
Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced HepatocarcinomaAdvanced HepatocarcinomaNCT01418729Hospital Donostia216